LAIYANG, China, May 16 GenesisPharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GTEC) ("Genesis" or the"Company"), a leading pharmaceutical company in the People's Republic of China,today announced that it had donated medicines with a total value of RMB3.0million (approximately US$428,000) to Sichuan Earthquake relief. Thesemedicines were shipped to Sichuan on 8:00AM May 16, 2008 Beijing Time.
"We are extremely grieved to know that people lost their lives and theirhomes as a result of the earthquake on May 12, 2008. It has been reported thatup to now at least twenty thousand people lost their lives. Many more wereseverely injured and their lives are threatened as a result of a shortage ofmedicine," said Mr. Wubo Cao, Chairman and Chief Executive Officer of Genesis."We feel obligated to show our love and support to the rescue efforts. We hopemore lives can be saved and the Sichuan people will be able to recover fromthe earthquake disaster earlier."
About Genesis Pharmaceuticals Enterprises, Inc.
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engagedin the research, development, production, marketing and sales ofpharmaceutical products in the People's Republic of China. Its operations arelocated in Northeast China in an Economic Development Zone in Laiyang City,Shandong province. Genesis is a major pharmaceutical company in Chinaproducing tablets, capsules, and granules for both western and Chineseherbal-based medical drugs.
Safe Harbor Statement
Certain statements in this press release that are not historical facts are"forward-looking statements" within the meaning of the Private SecuritiesLitigation Reform Act of 1995. Such statements are not guarantees of futureperformance and are subject to risks and uncertainties that could cause theCompany's actual results and financial position to differ materially fromthose included within the forward-looking statements. Forward-lookingstatements involve risks and uncertainties, including those relating to theCompany's ability to introduce, manufacture and distribute new drugs. Actualresults may differ materially from anticipated or predicted results, andreported results should not be considered as an indication of futureperformance. The potential risks and uncertainties include, among others, theCompany's ability to obtain raw materials needed in manufacturing, thecontinuing employment of key employees, the failure risks inherent in testingany new drug, the possibility that regulatory approvals may be delayed orbecome unavailable, patent or licensing concerns that may include litigation,direct competition from other manufacturers and product obsolescence. Moreinformation about the potential factors that could affect the Company'sbusiness and financial results is included in the Company's filings, availablevia the United States Securities and Exchange Commission.For more information, please contact: Genesis Pharmaceuticals Enterprises, Inc. Ms. Elsa Sung CFO Tel: 954-727-8436 Email: firstname.lastname@example.org Web: http://www.genesis-china.net CCG Elite Investor Relations, Inc. Mr. Crocker Coulson, President Tel: 646-213-1915 Email: email@example.com Web: http://www.ccgelite.com
SOURCE Genesis Pharmaceuticals Enterprises, Inc.